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Abstract: In addition to its usage for the study of biomolecules in living 
systems, bioorthogonal chemistry has emerged as a promising 
strategy to enable protein or drug activation in a spatially and 
temporally controlled manner. This study demonstrates the 
application of the bioorthogonal inverse electron-demand Diels-Alder 
(IEDDA) reaction to cleave trans-cyclooctene (TCO) and vinyl 
protecting groups from carboxylic acid-containing molecules. The 
TCO tetrazine-mediated decaging reaction proceeded under 
biocompatible conditions with fast reaction kinetics (< 2 minutes). 
Anti-inflammatory activity of ketoprofen was successfully reinstated 
after decaging of the nontoxic TCO-prodrug in live macrophages. 
Overall, this work expands the scope of functional groups and the 
application of decaging reactions to a new class of drugs.  
Early research in the field of bioorthogonal chemistry focused on 
ligation reactions such as the Staudinger reaction,[1] copper-
catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC),[2,3] 
palladium-catalysed cross-couplings,[4] ruthenium-catalysed 
olefin metatheses,[5] strain-promoted azide-alkyne cycloaddition 
(SPAAC),[6] tetrazole photoinduced 1,3-dipolar cycloadditions,[7,8] 
and inverse electron-demand Diels-Alder (IEDDA) tetrazine 
ligation.[9,10] Of these, the IEDDA reaction between trans-
cyclooctene (TCO) and a tetrazine is one of the more selective 
and fastest reported bioorthogonal reactions to date.[11] Since it 
was first introduced by Fox et al.,[9] this reaction has been used in 
innumerous biological applications such as cell and in vivo 
pretargeting imaging.[12–14] Recently, bioorthogonal cleavage 
reactions have emerged as promising strategies to control the 
activation of caged proteins, fluorophores, and small molecule 
drugs in living systems.[15] The TCO-tetrazine IEDDA ligation 
reaction can be re-engineered into a cleavage reaction by placing 
a leaving group at the allylic position of TCO. After the initial 
cycloaddition and elimination of nitrogen, the 4,5-
dihydropyridazine now contains an appropriately placed 
substituent that eliminates upon tautomerisation.[10] The group of 
Robillard reported the first use of the TCO-tetrazine reaction for 
bioorthogonal decaging to release amine-containing drugs 
(Figure 1a), in which they demonstrate the release of doxorubicin 
from a TCO carbamate prodrug in vitro.[16] They then apply this 
‘click-to-release’ strategy to successfully trigger the release of 
doxorubicin (Dox) and monomethyl auristatin E (MMAE) from an 
antibody-drug conjugate (ADC).[17,18] Mejia-Oneto and co-workers 
also reported targeted in vivo activation of a Dox-TCO carbamate 
prodrug by injecting an alginate hydrogel modified with tetrazines 
near the tumour site.[19] A limitation of the click-to-release strategy 
is the need for the delivery, and therefore optimization of the 
pharmacokinetic properties, of both the prodrug and the 
tetrazine.[20,21] However, the previously mentioned approaches 
are demonstrative of the potential of bioorthogonal decaging 
reactions for targeted drug-activation in vivo. 
 
Figure 1. Bioorthogonal decaging reactions. a. Reported TCO carbamate linker 
for amine release, successfully applied in vivo for doxorubicin and MMAE 
activation. b. Reported vinyl decaging for alcohol release, limited by its slow 
reaction rate. c. Reported TCO ether linker for the rapid release of alcohols. d. 
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Reported TCO ester for the release of carboxylic acids (model compounds 
benzoic acid and . e. Activation of anti-inflammatory drug ketoprofen in live cells 
from a stable TCO ester prodrug. 
Bioorthogonal chemistry has also been applied for the release 
of alcohols. Our group[22] and the groups of Bradley[23] and 
Devaraj[24] independently reported the use of the vinyl ether 
protecting group which could be cleaved by reaction with 
tetrazines to release alcohols (Figure 1b). This is, however, 
significantly slower than the TCO reaction for the release of 
amines. In addition, Robillard recently reported bioorthogonal 
cleavage of ethers, carbonates and esters from TCO to release 
alcohols (Figure 1c) or carboxylic acids (Figure 1d), respectively. 
However, the reported TCO-protected carboxylic acids proved 
highly unstable (~90% fragmentation in 50% mouse serum at 
37°C). In addition, the ether linker was only successfully used to 
deprotect tyrosine and control cell growth in tyrosine-free 
medium.[25]  
Previous examples of drug release have so far been limited 
to the release of amine- (Figure 1a) or alcohol-containing (Figure 
1b,c) anticancer drugs. These groups, although often found in 
small molecule drugs, are not always present and may not be vital 
for the function of the drug, meaning chemical modification at this 
site to form a prodrug does not lead to reduced activity. For this 
reason, it is important to expand the scope of bioorthogonal 
decaging reactions to include other functional groups. For 
example, non-steroidal anti-inflammatory drugs (NSAIDs) are an 
important class of drugs that contain a carboxylic acid group 
essential for their function.[26] Herein, we expanded the application 
of bioorthogonal cleavage reactions to the carboxylic acid 
functional group. A stable TCO-protected NSAID was 
successfully decaged in the presence of tetrazine within 2 minutes 
(Figure 1e) enabling the reinstatement of anti-inflammatory 
activity in living macrophages. 
Initially, following on from previous work in our group on the 
vinyl ether handle on alcohols,[22] we investigated the protection 
of carboxylic acids with the vinyl group (Figure 2). Computational 
studies on the reaction between vinyl acetate and different 
tetrazines 1–5 (Figure 2a) predicted that the first cycloaddition 
step was rate determining (SI, Figure S20), and that all tetrazines 
should have similar reactivity, with the exception of 
dimethyltetrazine 5 which was predicted to be the least reactive 
(SI, Tables S1, S3). The kinetics of the cycloaddition were 
experimentally determined with these tetrazines and the test 
substrate vinyl propionate 6 (SI, Figure S1). The fastest rate 
occurred with tetrazine 4, a mono-substituted tetrazine bearing a 
moderately electron-withdrawing group (benzoic acid, Figure 2b). 
It has previously been shown that tetrazines bearing strong 
electron withdrawing substituents have faster rates for 
cycloadditions while a small, non-bulky group increases the rate 
of the elimination step.[27] Next, the stability of tetrazines 1–5 in 
50% DMSO/H2O was assessed by monitoring the UV absorbance 
at 530 nm (SI, Figure S2). Tetrazine 1 showed moderate stability 
(t1/2 = 15.8 h) and tetrazine 2 was the most unstable (t1/2 = 5.7 h). 
Tetrazines 3–5 proved highly stable (~85 - 90% intact after 24 h, 
SI, Figure S2). The biological stability of tetrazine 4 was then 
assessed and it proved to be stable in cell culture media, 
phosphate-buffered saline (PBS) pH 7.4, and 10% plasma for at 
least 24 h (SI, Figure S3). Therefore, we decided to use tetrazine 
4 in further studies. 
 
Figure 2. Decaging of vinyl esters. a. Tetrazines used in this study. b. Kinetics 
of the cycloaddition step for the reaction of vinyl propionate with different 
tetrazines determined by following the decay of the UV absorbance of the 
tetrazine at 530 nm. n.d. = not determined. 
Ketoprofen 8 is a NSAID with a chiral centre. Although it is 
used as a racemate, the anti-inflammatory activity of ketoprofen 
mainly resides with the S-enantiomer. While the R-enantiomer is 
approximately 100 to 1000 times less potent than the S-
enantiomer as a cyclooxygenase inhibitor, research has shown 
that the R-enantiomer is still important in that it contributes to the 
analgesic effect of ketoprofen.[28] We started by converting 
ketoprofen into the vinyl ester 9 using palladium coupling[29] which 
proved stable in PBS pH 7.4 (SI, Figure S4). However, limited 
stability (assessed by High-Performance Liquid Chromatography 
(HPLC)) was observed in 10% plasma (t1/2 = 12 min) and cell 
culture media (t1/2 = 4 h) likely because the vinyl group does not 
provide steric protection of the ester group from nucleophilic 
attack and subsequent hydrolysis. This fact, along with the slow 
rate of reaction (approx. 20% of free drug observed after 24 h with 
30 equiv. of tetrazine, SI, Figure S5) resulted in the vinyl handle 
being abandoned, as its use for in vivo applications would be 
rather limited.  
Next, we decided to investigate TCO as a caging group to 
render ketoprofen inactive. A more reactive alkene was 
necessary in order to make this a rapid, useful bioorthogonal 
cleavage reaction. Quantum mechanical calculations (SI, Table 
S2) suggested that the initial cycloaddition between TCO esters 
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and different tetrazines is much faster than with vinyl esters, 
causing the rate-limiting step to depend on the tetrazine 
substituents. Hence, while the initial cycloaddition step is rate-
limiting for dimethyl-tetrazine 5 (SI, Figure S22), for dipyridyl-
tetrazine 1 the allylic elimination step (decaging) is the rate-
limiting step (SI, Figure S21). Irrespective of which step 
determines the reaction rate, all reactions involving TCO acetate 
were calculated to be much faster than those with vinyl acetate 
(SI, Table S2). Of note, our calculations reproduced the 
experimentally observed trend of axial-TCO being slightly more 
reactive than its equatorial isomer (SI, Figures S21, S22). 
Concerning the isomerization of the dihydropyridazine 
intermediate necessary for carboxylate release (i.e. decaging), 
the proposed water-mediated shift (in which one water molecule 
adds to one of the imine moieties and is subsequently β-
eliminated) appears to be more favourable than direct water-
assisted imine-enamine tautomerization (SI, Figure S23). 
We started by assessing the stability of the TCO ester bond. 
For this, we used cis-cycloocten-1-ol 10 to test both synthetic 
feasibility and stability of the ester bond. The cis-protected 
ketoprofen drug 11 was synthesised in 75% yield (SI) and, unlike 
the vinyl ester, proved to be stable in cell media, PBS pH 7.4, and 
10% plasma (only 5% free drug after 24 h) (SI, Figure S6). We 
propose that this increase in stability is due to the increased steric 
hindrance at the ester bond due to the TCO handle compared with 
the vinyl handle. It appears that significant steric hindrance is 
required on both sides of the ester bond and the ester proves 
unstable if either the protecting group (vinyl handle) or active 
molecule (in the case of the TCO-esters reported by Robillard)[25] 
are not sterically bulky. In the case of 12, a stereocentre α to the 
ester bond provides steric protection on one side as does TCO on 
the other. 
With these results in hand, we decided to further evaluate the 
TCO ester for bioorthogonal IEDDA decaging. Repeating the 
synthesis with trans-cycloocten-1-ol resulted in the desired 
product 12 with approximately 50% of the TCO isomerizing to the 
cis form (Figure 3a). This highlights a common problem with 
synthesising TCO-functionalised molecules. The isomerization of 
cis to trans using UV light is very low yielding and is not always 
suitable for the final step in syntheses that need a large amount 
of valuable drug. However, TCO’s highly reactive double bond is 
not compatible with several reaction conditions, such as the halide 
ions used in the formation of the acyl chloride intermediate. In 
addition to the modes of chirality on the cis and trans isomers of 
the TCO protecting group, ketoprofen also has a chiral center. 
Indeed, using thionyl chloride as an activating agent we observed 
the formation of 8 diastereomers by HPLC (Figure 3b) from the 
cis and trans isomers of TCO and the chiral center of the 
protected ketoprofen. Using chiral HPLC we were able to 
separate each diastereomer, analyse them by NMR and 
characterize the four trans isomers as enantiomeric pairs of either 
the axial 12ax or equatorial 12eq isomer (Figure 3c). Since the axial 
TCO-isomer has previously been shown to have different reaction 
rates than the equatorial isomer, each enantiomeric pair of axial 
and equatorial isomers were combined. We demonstrated a 
method of separating isomers of TCO and successfully overcame 
the isomerization problem commonly experienced in synthesis 
using TCO, even in the challenging case of having an additional 
chiral center on the drug. Now, although a low yield may be 
obtained, it is possible to subject TCO to reaction conditions that 
readily cause isomerization and still obtain the pure trans isomer 
at the end. 
 
Figure 3. Studies of TCO-ketoprofen ester. a. Synthesis of TCO-protected 
ketoprofen resulted in 84% yield of the product as a mixture of cis and trans-
isomers (NMR ratio 51:49 cis:trans). b. Separation of the 8 product 
diastereomers using HPLC. c. Alkene region from 1H NMR spectra of trans-
products. 
Reaction of TCO ketoprofen (axial and equatorial isomers) 
with tetrazine 4 (Figure 4a, SI, Figure S7) was then studied by 
HPLC over time. Considering the fast kinetics observed for the 
decaging, an excess of free TCO was added to quench the 
reaction at various time points. Liquid Chromatography-Mass 
Spectrometry (LC-MS) analysis of the quenched solution showed 
similar reaction profiles and decaging yields for both isomers, 
therefore further tetrazines were tested with only the axial isomer. 
The reaction of TCO-ketoprofen was then studied with tetrazines 
1,3 and 5 (tetrazine 2 was not chosen due to its high instability 
compared to other tetrazines, SI, Figure S2). For tetrazines 1, 3 
and 4, TCO-ketoprofen is consumed within 30 seconds and after 
2 minutes the change in the amount of ketoprofen is negligible 
(Figure 4b and SI, Figure S8) which is in good agreement with the 
low activation barriers predicted computationally. The observed 
accumulation of dihydropyridazine intermediate(s) A/B (Figure 
4b) demonstrates our prediction (for tetrazine 1, SI, Figure S21) 
that elimination of the carboxylate after IEDDA is the rate limiting 
step. In agreement with computational predictions, tetrazine 5 
showed a different reaction profile (SI, Figure S8). In this case, no 
significant amount long-lived intermediate was observed, 
indicating that the elimination is much quicker and therefore, for 
this tetrazine, it is the cycloaddition step which is rate limiting. This 
is also confirmed by the much slower disappearance of TCO-
ketoprofen and the corresponding formation of ketoprofen (not 
complete after 2 min). It is also important to note that the three 
tetrazines with the same rate determining step all show 
comparable decaging yields (~25%). Interestingly, Tetrazine 5, 
which showed no reaction with vinyl ketoprofen, gives a decaging 
yield double that of the other tetrazines (54%, Figure 4c). This 
highlights the fact that different tetrazines are optimal for different 
decaging reactions. Next, the effect of water content and pH on 
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decaging yield were assessed (Figure 4d and SI, Figures S9-12). 
Tetrazine 3 was chosen as a representative example of tetrazines 
1,3 and 4. It was shown that the reaction yield increased from 26% 
(0% water) to 33% (75% water), however no increase in yield was 
observed by the addition of 1% formic acid. Conversely, tetrazine 
5 showed no increase in yield upon increasing water 
concentration. However, the yield was increased to 65% by the 
addition of 1% formic acid (Figure 4d). This study highlights the 
importance of optimising the tetrazine for the decaging reaction 
as changing the tetrazine substituents can alter the rate-limiting 
step of the reaction, resulting in different kinetics and yields of 
decaging.  
 
Figure 4. Studies of TCO-ketoprofen ester. a. Mechanism of tetrazine-triggered 
TCO ester decaging reaction. b. LC–MS trace for the reaction of TCO-
ketoprofen 12ax with tetrazines 4 and 5 that demonstrates the ketoprofen release 
from TCO-ester prodrug after 30 seconds (tetrazine 4). c. Decaging yield of the 
reaction of TCO-KTP 12ax with tetrazines 1, 3, 4 and 5 assessed by LC-MS. 
Concentration of the released drug was determined by HPLC/UV using a 
calibration curve prepared with ascending concentrations of ketoprofen. d. 
Effect of water content and the addition of 1% formic acid on the decaging yield 
for reaction with tetrazines 3 and 5, which both have a different rate determining 
step. 
The promising stability and decaging results prompted us to 
further evaluate the application of this strategy in live cell studies. 
Using the macrophage cell line RAW264.7 (ATCC® T1B-71), we 
started by establishing the non-toxic concentrations of each 
compound (SI, Figure S13, S14). Although tetrazine 5 results in a 
higher decaging yield by LC-MS, this tetrazine proved toxic to 
macrophages even at low concentrations (~70% viability at 5 μM). 
Furthermore, the volatility of this tetrazine made it impractical for 
use in cell experiments. Tetrazine 4 was chosen for further studies 
as it proved to be non-toxic at high concentrations (~90% viability 
at 148 μM). Surprisingly, the anti-inflammatory effect of tetrazines 
and their reactivity with nitric oxide was observed as previously 
described (SI, Figure S15).[30] However, a concentration of 
tetrazine (50 μM) was chosen such that no anti-inflammatory 
activity was observed.  
Inflammation was induced on macrophages by using 
lipopolysaccharide (LPS, SI, Figure S16 for optimisation of 
concentration) and the anti-inflammatory effect of the 
bioorthogonal pair (TCO-ester 12 and tetrazine 4) was assessed 
using the Griess assay (Figure 5a). By monitoring the levels of 
nitric oxide (NO), we verified that when TCO-ketoprofen 12 was 
reacted with tetrazine 4 on LPS-stimulated macrophages a 
significantly enhanced anti-inflammatory effect was observed 
after 11 h (Figure 5b) (p < 0.001 for equatorial, p < 0.01 for axial). 
This reduction in inflammation corresponds to the successful 
cleavage of the TCO-ester bond from the caged drug leading to 
the release of ketoprofen.  During our studies, we also observed 
that ketoprofen itself failed to reduce the NO levels, while TCO-
ketoprofen 12 has a moderate effect on reducing NO levels 
(Figure 5b). This is likely due to the poor membrane permeability 
of the ketoprofen when compared to the caged drug. When 
protected as the TCO-ester, the cell permeability of ketoprofen 
was greatly improved, leading to a higher concentration of free 
drug in the cell as assessed by HPLC (Figure 5c). Briefly, this 
study involved incubation of cells for 24 h with either the prodrug 
or free drug. Subsequent HPLC analysis of the extracellular 
media revealed that almost no prodrug was detected while a 
significant amount of ketoprofen was still observed (Figure 5c). 
After 24 h, the level of NO from the prodrug alone was the 
same as the bioorthogonal pair (SI, Figure S17). While we 
expected the caged drug to show very little anti-inflammatory 
activity, this result suggested that activation might also happen 
without the tetrazine trigger. It is worth mentioning once again that 
the ester bond was shown to be fully stable in complete cell 
culture media for 24 h at 37 ºC. Therefore, this observation may 
be due to the hydrolytic enzymes inside the cell, which was 
confirmed by a reaction carried out with TCO-ketoprofen and 
esterase from porcine liver (SI, synthesis section). After 4 h, a 
small amount of ketoprofen was already released, and the amount 
increased over the next 20 hours to a yield of 71% for the axial 
isomer and 14% for the equatorial. The release of carboxylic acids 
from ester prodrugs via intracellular esterases has been widely 
reported.[31–33] Although enzyme-mediated hydrolytic activation of 
TCO-ketoprofen was observed, the nearly spontaneous release 
of the active drug after tetrazine reaction suggests that this 
approach may play an important role in biological applications. 
For example, we anticipate that an ADC could be used to target 
the ester prodrug to extracellular receptors expressed on 
macrophages which would allow the fast and local delivery of 
ketoprofen at sites of inflammation.  
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Figure 5. Live cell decaging experiments a. Tetrazine-mediated decaging of 
TCO-ketoprofen ester in live macrophages. Initial inflammation triggered by LPS 
causes an increase in the concentration of nitric oxide and prostaglandin E2 b. 
Griess assay used to determine the concentration of nitric oxide. Decaging of 
TCO-ketoprofen prodrug resulted in decreased NO concentrations. c. 
Concentration of TCO-ketoprofen 12 and ketoprofen 8 present in the media after 
24 h after incubation of either 12ax, 12eq or 8. The high presence of ketoprofen 
that remains in the media confirms the relatively poor membrane permeability 
of ketoprofen 8. Results are expressed as an average of three independent 
experiments. d. ELISA used to determine the concentration of PGE2. Decaging 
of TCO-ketoprofen prodrug resulted in decreased concentrations of PGE2. 
The levels of inflammation were then assessed using an 
enzyme-linked immunosorbent assay (ELISA, R&D Systems) to 
monitor the levels of prostaglandin E2 (PGE2) (Figure 5d), which 
has been shown to be overexpressed in this cell line when 
inflammation is stimulated by LPS.[34] Briefly, this assay uses a 
monoclonal antibody that competitively binds both PGE2 in the 
samples and PGE2-alkaline phosphatase molecules. The alkaline 
phosphatase produces a chromogenic signal upon the addition of 
p-nitrophenyl phosphate. Therefore, the concentration of PGE2 
present in a sample is inversely proportional to the absorbance 
produced by the bound enzyme (SI, Figure S18). Cells with only 
LPS showed the highest level of PGE2 (4060 pg/mL), which 
confirmed that inflammation was successfully stimulated. A 
similarly high concentration (4010 pg/mL) was observed with the 
tetrazine, confirming that the tetrazine alone does not have an 
anti-inflammatory effect. Despite the poor cell permeability of 
ketoprofen, cells incubated with ketoprofen showed the lowest 
level of PGE2 (215 pg/mL). The anti-inflammatory effect of 
ketoprofen can be seen using this assay as the ELISA has a 
higher sensitivity than the Griess assay (detection limit 0.5 μM). 
TCO-ketoprofen 12 also showed lower levels of PGE2 than the 
LPS control (12ax: 686 pg/mL, 12eq: 486 pg/mL).  The 
bioorthogonal pair resulted in a statistically significant reduction in 
PGE2 concentration compared to the prodrug alone (12ax + 4: 193 
pg/mL, 12eq + 4: 200 pg/mL) (p < 0.001 for axial, p < 0.01 for 
equatorial). It was observed that the concentration of PGE2 was 
the same for the bioorthogonal pair as for free ketoprofen, 
therefore confirming that the anti-inflammatory activity was 
successfully reinstated up decaging in live macrophages. 
In summary we describe the bioorthogonal tetrazine-triggered 
release of carboxylic acid-containing molecules and demonstrate 
the application on a new class of anti-inflammatory drugs. In doing 
so, we have expanded the bioorthogonal drug activation strategy 
to encompass a wider range of drugs and diseases. Finally, this 
approach may also find utility for protein activation where 
carboxylic acid side-chains can be caged/decaged. 
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